Literature DB >> 27502718

Utilisation of the ESMO-MCBS in practice of HTA.

C Wild1, N Grössmann2, P V Bonanno3, A Bucsics4, J Furst5, K Garuoliene6, B Godman7,8, J Gulbinovič9, J Jones10, M K Pomorski11, R Emprechtinger2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27502718     DOI： 10.1093/annonc/mdw297

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  14 in total

1.  Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries.

Authors:  Alice Pisana; Björn Wettermark; Amanj Kurdi; Biljana Tubic; Caridad Pontes; Corinne Zara; Eric Van Ganse; Guenka Petrova; Ileana Mardare; Jurij Fürst; Marta Roig-Izquierdo; Oyvind Melien; Patricia Vella Bonanno; Rita Banzi; Vanda Marković-Peković; Zornitsa Mitkova; Brian Godman
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

Review 2.  Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems.

Authors:  Dario Trapani; Giuseppe Curigliano; Alexandru Eniu
Journal:  Breast Care (Basel)       Date:  2019-09-24       Impact factor: 2.860

3.  The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis.

Authors:  Lin-Guang-Jin Wu; Dan-Ni Zhou; Ting Wang; Jun-Zhi Ma; Hua Sui; Wan-Li Deng
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

Review 4.  Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.

Authors:  Patricia Vella Bonanno; Michael Ermisch; Brian Godman; Antony P Martin; Jesper Van Den Bergh; Liudmila Bezmelnitsyna; Anna Bucsics; Francis Arickx; Alexander Bybau; Tomasz Bochenek; Marc van de Casteele; Eduardo Diogene; Irene Eriksson; Jurij Fürst; Mohamed Gad; Ieva Greičiūtė-Kuprijanov; Martin van der Graaff; Jolanta Gulbinovic; Jan Jones; Roberta Joppi; Marija Kalaba; Ott Laius; Irene Langner; Ileana Mardare; Vanda Markovic-Pekovic; Einar Magnusson; Oyvind Melien; Dmitry O Meshkov; Guenka I Petrova; Gisbert Selke; Catherine Sermet; Steven Simoens; Ad Schuurman; Ricardo Ramos; Jorge Rodrigues; Corinne Zara; Eva Zebedin-Brandl; Alan Haycox
Journal:  Front Pharmacol       Date:  2017-08-23       Impact factor: 5.810

5.  Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?

Authors:  Nicole Grössmann; Claudia Wild
Journal:  ESMO Open       Date:  2017-01-31

6.  Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules.

Authors:  Urania Dafni; Dimitris Karlis; Xanthi Pedeli; Jan Bogaerts; George Pentheroudakis; Josep Tabernero; Christoph C Zielinski; Martine J Piccart; Elisabeth G E de Vries; Nicola Jane Latino; Jean-Yves Douillard; Nathan I Cherny
Journal:  ESMO Open       Date:  2017-10-09

7.  Development of the First Value Assessment Index System for Off-Label Use of Antineoplastic Agents in China: A Delphi Study.

Authors:  Qian Jiang; Wei Zeng; Jiajie Yu; Hui Liu; Mian Mao; Youping Li
Journal:  Front Pharmacol       Date:  2020-06-16       Impact factor: 5.810

8.  Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Wânia Cristina da Silva; Vânia Eloisa de Araujo; Ellias Magalhães E Abreu Lima; Jessica Barreto Ribeiro Dos Santos; Michael Ruberson Ribeiro da Silva; Paulo Henrique Ribeiro Fernandes Almeida; Francisco de Assis Acurcio; Brian Godman; Amanj Kurdi; Mariângela Leal Cherchiglia; Eli Iola Gurgel Andrade
Journal:  BioDrugs       Date:  2018-12       Impact factor: 5.807

9.  Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplished-What is Next?

Authors:  John G Gribben; Elisabeth de Vries; Nathan I Cherny; Pieter Sonneveld
Journal:  Hemasphere       Date:  2020-04-01

10.  Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies.

Authors:  Mihajlo Jakovljevic; Tetsuji Yamada
Journal:  Front Pharmacol       Date:  2017-09-21       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.